SCHEMBL5486293

SCHEMBL5486293

FC(F)(F)c1ccccc1C(F)(F)F.OBO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.45
LMNA P02545 1/20 0.45
ALDH1A1 P00352 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
POLB P06746 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
NFKB1 P19838 1/20 0.43
IDO1 P14902 2/20 0.41
CA2 P00918 1/20 0.41
TSHR P16473 1/20 0.41
GRIN2D O15399 2/20 0.39
GRIN3B O60391 2/20 0.39
GRIN1 Q05586 2/20 0.39
GRIN2A Q12879 2/20 0.39
GRIN2B Q13224 2/20 0.39
GRIN2C Q14957 2/20 0.39
GRIN3A Q8TCU5 2/20 0.39
PDK2 Q15119 1/20 0.39
HSD11B1 P28845 1/20 0.39
KIF11 P52732 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27999682 0.88 HSD11B1 (0.42) GAALMNAALDH1A1TDP1POLB
SCHEMBL63469 0.87 ALDH1A1 (0.52) GAALMNAALDH1A1TDP1POLB
SCHEMBL29441997 0.87 ALDH1A1 (0.52) GAALMNAALDH1A1TDP1POLB
SCHEMBL4878669 0.85 KCNN4 (0.41) GAALMNAALDH1A1TDP1POLB
Hydrogen Sulfide SCHEMBL28274662 0.84 ALDH1A1 (0.50) GAALMNAALDH1A1TDP1POLB
Iodide SCHEMBL29093541 0.81 ALDH1A1 (0.48) GAALMNAALDH1A1TDP1POLB
Bromide SCHEMBL29093546 0.81 ALDH1A1 (0.48) GAALMNAALDH1A1TDP1POLB
SCHEMBL7785251 0.79 GAA (0.39) GAALMNAALDH1A1TDP1POLB
SCHEMBL2380334 0.79 LMNA (0.46) GAALMNAALDH1A1TDP1POLB
SCHEMBL22827 0.78 ATM (0.48) GAALMNACA2TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250410-B2 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof VIA PHARMACEUTICALS, INC. (US) 2007-07-31 US disclosed
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof BAY CITY CAPITAL LLC 2004-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152888-A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses thereof PDE7A, PDE3B, PDE3A GAA 266/4885LMNA 1410/4885ALDH1A1 395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.